What ALTRIA GROUP, INC.'s SEC filings said

10-Q for 2026Q3, filed 29 Oct 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Oral Tobacco Revenue and Margins72 · importance in its document · 10-Q · 2026Q3
For the nine months ended September 30, 2026, oral tobacco net revenues fell 1.2% to $2.070 billion, as a $140 million decline from shipment volume was partly offset by $121 million from higher pricing, including higher promotional…
Dividends and Capital Returns69 · importance in its document · 10-Q · 2026Q3
Altria paid $5.330 billion in dividends during the first nine months of 2026, up 3.0% from $5.175 billion in the prior-year period. In August 2026, the Board increased the quarterly dividend 4.7%, from $1.06 to $1.11 per share, bringing…
Settlement and FDA Payments66 · importance in its document · 10-Q · 2026Q3
Altria estimated average charges to cost of sales of $3.0 billion annually for the next three years for State Settlement Agreement payments and FDA user fees, based on current agreements and estimates. Payments for these items totaled…
Guidance / Outlook62 · importance in its document · 8-K exhibit · 29 Oct 2026
Altria raised its 2026 full-year adjusted diluted EPS guidance to $5.66–$5.74, from a 2025 base of $5.42, representing growth of 4.5%–6.0%. The outlook contemplates increased macroeconomic uncertainty facing adult nicotine consumers and…
Guidance raised60 · rule score among filings · 8-K Item 2.02 · 29 Oct 2026
Raises 2026 Full-Year Earnings Guidance RICHMOND, Va. - October 29, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2026 third-quarter and nine-months business results and raises our guidance for 2026 full-year adjusted diluted…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 29 Oct 2026

Full report · Filing on EDGAR

Oral Tobacco Revenue and MarginsImportance 72
For the nine months ended September 30, 2026, oral tobacco net revenues fell 1.2% to $2.070 billion, as a $140 million decline from shipment volume was partly offset by $121 million from higher pricing, including…
Dividends and Capital ReturnsImportance 69
Altria paid $5.330 billion in dividends during the first nine months of 2026, up 3.0% from $5.175 billion in the prior-year period. In August 2026, the Board increased the quarterly dividend 4.7%, from $1.06 to $1.11…
Settlement and FDA PaymentsImportance 66
Altria estimated average charges to cost of sales of $3.0 billion annually for the next three years for State Settlement Agreement payments and FDA user fees, based on current agreements and estimates. Payments for…
State Tobacco RestrictionsImportance 59
As of October 26, 2026, California, Massachusetts, New Jersey, New York, Rhode Island, Utah and the District of Columbia had enacted flavor restrictions affecting tobacco products; California’s law covers most flavored…
Operating Income and MarginsImportance 54 · +1 more on this subject
For the nine months ended September 30, 2026, operating income increased 14.0% to $9,405 million from $8,248 million, primarily because OCI was higher and the prior-year comparison included an $873 million non-cash…
Excise Tax TrendsImportance 54
Excise taxes on products declined 10.8% to $2,116 million for the nine months ended September 30, 2026, from $2,373 million in the prior-year period. For the third quarter, excise taxes declined 15.8%, a $130 million…
E-Vapor Goodwill ImpairmentImportance 52
Altria recorded a non-cash, pre-tax impairment charge of $873 million for the nine months ended September 30, 2025 to reduce the e-vapor reporting unit’s goodwill to estimated fair value. The impairment followed the…
Liquidity and Debt PositionImportance 49
At September 30, 2026, Altria held $2.7 billion in cash and cash equivalents and had up to $3.0 billion available under its senior unsecured revolving credit agreement; the company reported compliance with the…
Oral Tobacco Demand WeaknessImportance 49
Altria’s oral tobacco products segment domestic shipment volume fell 5.4% in the first nine months of 2026, or an estimated 5% after adjusting for trade inventory movements, as retail share losses and inventory…
Revenue Performance and MixImportance 42
For the nine months ended September 30, 2026, Smokeable Products net revenues were $13.532 billion, up $465 million (3.6%), while reported OCI increased $327 million (3.9%) to $8.668 billion and adjusted OCI rose $345…
Operating Cash Flow TrendsImportance 42
Net cash provided by operating activities increased to $6.151 billion in the first nine months of 2026 from $6.019 billion in the comparable 2025 period. The increase primarily reflected lower State Settlement…
Equity Investment IncomeImportance 41
For the nine months ended September 30, 2026, income or losses from investments in equity securities improved by $89 million, or 22.4%, primarily because of higher income from Altria’s ABI investment. In the third…

8-K filings last 12 months

Guidance raised29 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
“Raises 2026 Full-Year Earnings Guidance RICHMOND, Va. - October 29, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2026 third-quarter and nine-months business results and raises our guidance for 2026 full-year adjusted diluted…”
Read from the attached exhibit: Guidance / Outlook · Balance Sheet and Liquidity · Impairment and Exit Charges
New debt9 Oct 2026 · 8-K Item 1.01 · Routine · rule score 35
“Effective October 7, 2026, Altria Group, Inc. (“Altria”) entered into an extension agreement (the “2026 Extension Agreement”) to amend its $3.0 billion senior unsecured 5-year revolving credit agreement, dated as of October 24, 2023, as…”
Board change28 Aug 2026 · 8-K Item 5.02 · Routine · rule score 10
“On August 27, 2026, the Board of Directors (the “Board”) of Altria Group, Inc. (“Altria”) increased the size of the Board from 10 to 11 directors and elected Steven W. Presley to the Board, in each case, effective August 27, 2026.”
Read from the attached exhibit: Leadership Transition
Results (release not read)30 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
Read from the attached exhibit: Capital Expenditure Guidance · Guidance / Outlook · Restructuring and Capex
CEO exit, planned succession18 May 2026 · 8-K Item 5.02 · Flagged · rule score 60
“Consulting Agreement with Former CEO Mr. Gifford will serve as a consultant to Altria and its Board of Directors following his retirement to help facilitate an effective CEO and CFO transition and as a resource to the Board Directors and…”
Results (release not read)30 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
Guidance issued · Board change29 Jan 2026 · 8-K Items 2.02, 5.02 · Routine · rule score 25
“Provides 2026 Earnings Guidance RICHMOND, Va. - January 29, 2026 - Altria Group, Inc. (NYSE: MO) today reports our 2025 fourth-quarter and full-year business results and provides our guidance for 2026 full-year adjusted diluted earnings…”
Executive pay change11 Dec 2025 · 8-K Item 5.02 · Routine · rule score 5
“On December 8, 2025, William F. Gifford, Jr. informed the Board of Directors (the “Board”) of Altria Group, Inc. (“Altria”) of his decision to retire as a director of Altria and as Chief Executive Officer (“CEO”), effective May 14, 2026…”

Earlier reports

10-Q · 2026Q2filed 30 Jul 2026
Capital Expenditure Outlook · Settlement and FDA Payments · Liquidity and Debt Position

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.